Our analysis of the mutational status of pancreatic cancer and ZDHHC3 expression revealed that pancreatic cancer patients with high expression of ZDHHC3 had a higher proportion of KRAS and TP53 mutations, and pancreatic cancer patients carrying KRAS and TP53 mutations also had significantly higher levels of ZDHHC3 expression. Here, KRAS is linked to pancreatic neoplasm.